Summary A 4-day tumour sensitivity assay of potential use in predicting tumour response to cytotoxic drugs has been investigated in patients with chronic lymphocytic leukaemia. The method comprised isolation of white cells from peripheral blood, drug exposure and incubation'for 4 days. Drug-induced tumour cell kill was assessed by differential staining of dead and live cells such that the latter could be morphologically identified, with subsequent calculation of tumour cell viability. Concentrations of drug for use in the assay were chosen for chlorambucil (2jugmlP1), 4-hydroperoxy-cyclophosphamide (2ygml1)--which was used in vitro in place of cyclophosphamide-prednisolone (0.5 pg ml-') and vincristine (0. 
Since the 1950s, many investigators have tried to develop in vitro tests to predict the response of individual tumours to chemotherapy (for reviews, see Dendy, 1976; Von Hoff & Weisenthal, 1980; and Hamburger, 1981) . Of greatest interest in recent years have been the so-called tumour colony forming or stem cell assays (Courtenay & Mills, 1978; Hamburger & Salmon, 1977; Salmon et al., 1978 Salmon et al., , 1980 Von Hoff et al., 1981) . However, although these assays have a relatively sound theoretical basis, there are a number of practical difficulties: they are very time consuming; results can only be obtained from 25% of samples tested (Von Hoff et al., 1981) ; and some types of tumour cannot be tested at all.
Other methods that have been used include assays based on radioactive precursor incorporation (e.g. Volm et al., 1979 ; Group for sensitivity testing of tumors (KSST), 1981) and dye exclusion (e.g. Durkin et al., 1979) . These methods have not been as widely accepted, partly on account of the fact that a specific effect in the tumour cells could be masked by large numbers of non-tumour cells since both populations are assayed together.
Recently Weisenthal et al. (1983a, b, c) have reported a dye exclusion assay where, after 4 days incubation, live tumour cells can be stained, identified cytologically and enumerated separately from dead cells and non-tumour cells, thus constituting what could be termed a "tumour cell killing assay."
This assay has a number of advantages over other in vitro assays. It is simple, reproducible and has been applied to a broad spectrum of tumour types (Weisenthal et al., 1983a, b) . The assay (along with a similar assay incorporating duck red blood cells as an internal standard) compares favourably in both drug sensitivity and accuracy of clinical correlations with a standard colony forming assay (Weisenthal et al., 1983a, c) . Weisenthal et al. (1983c) also suggest that "dye exclusion tests may be specially valuable in assessing drug-induced cytotoxicity in non-dividing cells". For this reason, we have investigated the use of this dye-exclusion assay with samples from patients with chronic lymphocytic leukaemia (CLL) and have attempted to define a system by which future predictive in vivo/in vitro correlations could be determined. 
Patients
Blood was obtained from patients who were attending the hospital on an out-patient basis. Most were chosen because they were already undergoing, or were about to start, chemotherapy for their CLL. Diagnosis of CLL was based on the demonstration of a peripheral blood lymphocytosis and histological examination of bone marrow (5cases) or lymph node (5 cases) or both (3 cases). In one patient presenting with stage I disease, splenomegaly and thrombocytopenia developed gradually over 2 years. One patient was referred to the hospital and diagnostic criteria were not available. Patients were staged according to the method of Rai et al. (1975) .
Patients 1, 2, 3, 5, 10, 13 and 15 had received no cytotoxic drugs before the therapy with which a correlation was obtained, whereas the other patients had received chemotherapy for 1-6 years previously. Patients received 4-weekly courses of prednisolone (40mg for 5 days) either alone or in combination with chlorambucil (20-30mg for 2 days) or cyclophosphamide (200-300mg for 4 days) sometimes including vincristine (2mg i.v.). At least 3 months treatment was given before an assessment of response was made.
Clinical response was assessed by the criteria of Rai et al. (1975) . Patients achieving a complete or partial remission were taken to be sensitive for purposes of comparison with in vitro sensitivity, while those showing only clinical improvement or no-response were termed resistant.
As this work was mainly involved in setting up the assay system, most of the time it was not possible to evaluate the patients in ignorance of the in vitro result or vice versa.
Cell separation Blood (5-10 ml) was collected into lithium heparin or potassium EDTA tubes and then layered onto Lymphocyte separation medium (LSM; Flow Laboratories, Irvine, Scotland) for separation of the whole white cell population at 1 g. The cells remaining at the LSM interface were collected, washed twice and finally suspended in RPMI-FCS medium (RPMI 1640 medium containing 10% foetal calf serum, 20mM HEPES (N-2-hydroxyethylpiperazine-N'-2-ethanesulphonic acid), 2mM glutamine, 0.125 pgml-1 fungizone (all from Flow Laboratories) and 40 pg ml-' gentamycin).
They were counted and tested for viability using trypan blue. The cell preparations obtained by this procedure were consistently 99% viable.
Drug treatment
Cells were diluted to S x 105 ml-1 and 450 M1 placed in sterile polystyrene tubes. Drugs were added in 5Opul PBS to triplicate tubes. Twelve controls received 50pl PBS. Vc and Pred were left in for the entire 4-day period of the assay, whereas Chl and 4-Cy were removed after 1 h. To achieve this, cells were twice washed with 5 ml of FCS RPMI medium, centrifuged at 400g for 5min, and finally resuspended in 0.5 ml of fresh medium. This reduced the drug concentration to a calculated 0.1% of the original value. Six controls (for Chl and 4-Cy) received the washing procedure, the other 6 controls (for Vc and Pred) were not washed.
Staining of cells
All control and drug-treated tubes were incubated at 37°C for 4 days (a convenient time chosen by Weisenthal et al., 1983c) . After this 0.5ml of 2% fast green dye solution was added to each tube, which was briefly agitated with a whirlimix. The dye stains membrane permeable cells but is excluded by intact cells. After about 8min at room temperature, samples were whirlimixed again, vigorously agitated with a pasteur pipette and loaded into cytocentrifuge chambers at -105 cells per chamber. At 12min the samples were cytocentrifuged onto ethanol-washed slides at 1,250 rpm for 7 min and air dried.
Slides were counterstained through a series of solutions: modified haematoxylin (90 sec), 4 changes of 7.5% ethanol to lyse red blood cells (2 quick dips each), modified eosin (30sec) and 2 quick dips in each of 2 changes of 95% ethanol, absolute ethanol and xylene. Slides were then mounted with Eukitt mountant. With this procedure fast green stained cells retained the green colouring while live cells were counterstained with the haematoxylin and eosin.
Live cells were identified by standard morphological criteria (see Figure 1c) . It was not possible to identify the dead cells as all morphological features had been lost, but this did not affect the calculations of tumour cell viability (see below).
Cell counting and calculation Three categories of cells were counted on the slides: live tumour cells (NLT; i.e. number of live small lymphocytes), live normal cells (NLN; i.e. number of live non-tumour cells) and dead cells (ND; i.e. fast green stained cells) (see Table II These results suggest that under the conditions of the assay fast green accurately differentiates dead cells in both control and drug-treated cultures, and that LT values are not affected by loss of cells in the cytocentrifuging process.
Two major problems with dye exclusion assays are cell proliferation and autolysis and if these occurred, both of them would artificially increase the LT. In CLL, however, cell proliferation is <1% (Tannock, 1978) . To determine the extent of autolysis in the present assay, control and drugtreated samples from 5 patients were counted at the beginning and end of the experiment. The average cell loss was only 1.2% (s.d. = 6.8%, n= 30). No significant differences were found in the cell loss between control and drug-treated samples over the 4 days of the study.
Optimisation of culture conditions
Experiments were performed to determine important factors in obtaining the best control viabilities and cell morphologies. The whole assay was undertaken with media containing different types of serum, and different media were used in the cell washing procedure (at the end of 1 h drug incubations) and for dissolving the fast green stain.
Control viabilities in the assay using RPMI-FCS medium were little different whether the serum was heat-inactivated prior to use (LT = 30.7 + 23.5%, mean + s.d.; n = 74 samples from different patients) or not (22.9 +19.7%; 3 1). Replacement of the FCS by the patient's own (autologous) serum at a final concentration of 10% also had no effect on control viability (34.1 + 23.9%; 10). Collection of blood into potassium EDTA increased control viabilities (LT = 41.3 + 20.0%; 39). In addition < 5% of samples had a control viability of < 10%, compared with 18% when blood was collected into lithium heparin tubes. Control viabilities were similar whether round-or flatbottomed polystyrene tubes were used (LT=31.7±24.5%; 55 and 27.3 +21.4%; 18).
When 1 h drug incubations were performed, the cells were washed with two 5 ml aliquots of medium to remove residual drug. Best viabilities and cell morphologies at the end of the assay were obtained when cells were washed with RPMI-FCS medium.
Washing with either PBS or RPMI medium containing 10% newborn calf serum tended to reduce the cell viability and resulted in some cell ghosting.
Fast green dissolved in RPMI-FCS medium gave better morphology and viability than dissolving the dye in PBS according to Weisenthal et al. (1983a) . Difficulty was experienced, however, in filtering the fast green solution, and so, as fast green dissolved in serum-free RPMI medium gave equivalent results and filtered easily, it was used routinely in the assay.
Drug concentrationsfor use in vitro
Drug concentrations for use in vitro to predict for in vivo response were determined empirically to give the most accurate comparison with clinical response (as with other in vitro assays). First, an estimate of the possible range of drug concentrations was obtained from in vitro methods already published (Salmon et al., 1978; Von Hoff et al., 1981; Weisenthal et al., 1983a) or from pharmacological parameters such as concentration times time values (Nelson et al., 1980; Bosanquet & Gilby, 1982; Alberts & Chen, 1980) . Up to 5 different concentrations based on these figures were then used in the assay when the drug was first investigated.
Typical dose-response curves are shown for Chl in from the dose-response curves which gave a scatter of results in accordance with clinical experience of response (Desai et al., 1970; Han et al., 1973; Liepman & Votaw, 1978; Oken & Kaplan, 1979; Sawitsky et al., 1977) success of the assay was 100%, and this included repeat assays of the previous 3 patients whose cells were non-viable after 4 days in culture. Assays were often performed on cells taken from the same patient on consecutive visits to the hospital. In most cases the values of TCV obtained were remarkably similar over a period of several months. We are continuing to monitor the in vitro chemosensitivity of the responsive patients, to determine whether loss of in vitro sensitivity will predict for relapse in vivo. Table II gives the clinical details of the patients whose response was compared with in vitro chemosensitivity and Table III shows the details of these comparisons. The comparison was prospective (i.e. in vitro test performed just prior to each new drug schedule) in all cases except in patients 2, 6a, 9, 11 and 12 where the earliest successful in vitro assay result was used. It can be seen from Table III that the minimum TCV of the drugs the patients received agrees well with the in vivo response. Assay results From 10-50 tubes were set up for each patient for different controls, drugs and drug concentrations. At no time was the number of cells a limiting factor. The assay was technically successful (i.e. at least 4 drugs or drug concentrations could be successfully counted at the end of the assay) in 86% of samples received. Eleven of 76 (14%) assays performed were not successful for the following reasons: setting-up errors (2); staining errors (4); bacterial contamination (2) and no viable cells after 4 days in culture (3). When blood was collected into potassium EDTA, the technical
Discussion
The 4-day tumour cell chemosensitivity assay described in this paper avoids a major pitfall associated with other short term (i.e. <7 day) in vitro assays (for review see Von Hoff & Weisenthal, 1980) in that it measures kill of tumour cells specifically as distinct from that of both tumour and non-tumour cells. At the same time it does not have the technical limitations of the "stem cell" or "cloning" assays, which are time consuming, and only work in -25% of specimens received (Von Hoff et al., 1981) . Thus, although the stem cell assay is a highly sensitive test of tumour chemosensitivity, its major role increasingly seems to be in the area of preclinical antineoplastic drug screening (Weisenthal, 1981; Salmon et al., 1981) . By contrast, tumour cell assays measure the proportion of all tumour cells killed. Thus, whilst stem cell assays may be capable of predicting potential tumour cure, tumour cell assays may correlate more satisfactorily with tumour response as observed by the clinician.
Problems associated with dye exclusion assays We have followed the timing of Weisenthal et al., (1983a,c) using a 4-day incubation period for the assay to allow for drug-damaged cells to become membrane permeable whilst avoiding excessive loss of control viability. During the 4 days, both cell proliferation and autolysis could occur but while these may present problems for other tumour systems, both are minimal for CLL using the present assay.
Since the loss of membrane integrity is a late event in cell death, this assay may require higher drug concentrations than the stem cell assay to achieve equivalent cell kills (Wiesenthal et al., 1983c) . This difference in sensitivity and the time required for loss of membrane integrity have been largely ignored in work attempting to correlate and compare the 2 types of assay (Roper & Drewinko, 1976 Bhuyan et al., 1976) . This has led to the clearly erroneous conclusion that dye exclusion assays are inappropriate to measure drug-induced cell kill (Roper & Drewinko, 1979) .
One other potential problem with the present assay is that some lethally-damaged cells may take longer than 4 days to lose their membrane integrity and the extent to which this occurs may differ for each drug. However, for each drug a number of samples have shown good sensitivity, indicating that with the drug concentrations used, many of the cells have lost their membrane integrity by 4 days. In addition, no patients who have shown in vitro resistance have been sensitive in vivo indicating again that delayed death is not a major problem.
One problem common to all in vitro chemosensitivity assays is that of drug activity in vitro. Following Volm et al. (1979) (Salmon et al., 1978; Weisenthal et al., 1983a , Von Hoff et al., 1981 . Previously, in a preliminary report of this work, we investigated the use of the TCV averaged over the drugs given in vivo (Bosanquet et al., 1982) but here we have used the criteria of Von Hoff et al. (1981) requiring only one drug of a combination to be sensitive in vitro for comparison with the response in vivo. Using these criteria, it is essential that all the drugs given in combination to the patient are tested in vitro and we have only attempted a comparison when this condition is fulfilled. As with most other studies we have used a cut-off between sensitive and resistant of 30% TCV, which gave us 2 false positive comparisons (sensitive in vitro, resistant in vivo). This is higher than the value which would give us no false comparisons (25% TCV, see Table III ) but is preferable to the higher probability of false negative comparisons being obtained with this lower cut-off.
With the inherent errors in any in vitro assay, a definite cut-off line between sensitivity and resistance is likely to be of less value clinically than some form of graded probability of response. Thus we would say (Table III) that any TCV below -25% would predict for partial or complete response, whereas a value greater than -35% would most likely show no response or progressive disease despite chemotherapy. Intermediate values would most likely predict for clinical improvement.
The administration of drug combinations to patients who respond will always mean that it is never known which of the drugs has been active in vivo. However, if the in vitro results are shown to predict responsiveness accurately, then this lack of precise knowledge need not be a major limitation.
We have shown that the assay described here is a technically feasible approach to the in vitro determination of chemosensitivity in CLL and that this is in concordance with clinical response. Including the work of Weisenthal and colleagues (1983a, b) there are now 69 in vitro/in vivo comparisons or correlations of which only 4 are false (all sensitive in vitro, resistant in vivo). This compares very favourably with results obtained by the stem cell assay and suggests that this dye exclusion could be of considerable value in the prediction of tumour chemosensitivity. In addition, the assay is rapid, relatively simple to perform and requires small numbers of cells. We conclude, therefore, that this assay warrants wider investigation for the prediction of tumour chemosensitivity. To this end, we are now assessing the assay and its modified form (Weisenthal et al., 1983c) in a broader spectrum of tumour types using both phase-and cycle-specific drugs. We are also attempting to define optimum levels of , nitrogen mustard (HN2), 1-(2-chloroethyl)-cyclohexyl-l-nitrosourea (CCNU) and 2-deoxycoformycin for use in CLL.
